BUFFALO, NY- January 22, 2024 – On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center #published a new brief #report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.”
“In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I must accomplish a mission. If everything happens for a reason, my cancer, in particular, I must find out how metastatic cancer can be treated with curative intent. This is my mission now, and the reason I was ever born. In January 2023, I understood the meaning of life, of my life. I was born to write this article. In this article, I argue that monotherapy with targeted drugs, even when used in sequence, cannot cure metastatic cancer. However, preemptive combinations of targeted drugs may, in theory, cure incurable cancer. Also, I share insights on various topics, including rapamycin, an anti-aging drug that can delay but not prevent cancer, through my personal journey.”
DOI - https://doi.org/10.18632/oncoscience.593
Corresponding author - Mikhail V. Blagosklonny - Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com
Sign up for free Altmetric alerts about this article -
https://oncoscience.altmetric.com/details/email_updates?id=10.18632%2Foncoscience.593
Subscribe for free publication alerts from Oncoscience - https://www.oncoscience.us/subscribe/
Keywords - cancer, lung cancer, brain metastases, capmatinib, resistance, MET
About Oncoscience
Oncoscience is a traditional, peer-reviewed, bio-medical oncology research journal with FREE publication for authors and open-access for readers.
To learn more about Oncoscience, please visit https://www.oncoscience.us/ and connect with us:
Facebook - https://www.facebook.com/Oncoscience
X - https://twitter.com/OncoscienceJrnl
Instagram - https://www.instagram.com/oncosciencejrnl/
YouTube - https://www.youtube.com/@OncoscienceJournal
LinkedIn - https://www.linkedin.com/company/oncoscience/
Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957
